Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat

Neuropharmacology

Volumn 55, Issue 8, 2008, Pages 1321-1328

  Dupre, Kristin B ^a   Eskow, Karen L ^a   Barnum, Christopher J ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

5 HT1A receptor; D1 receptor; Dopamine; Dyskinesia; l DOPA; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; BENZAZEPINE DERIVATIVE; BIOGENIC AMINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; OXIDOPAMINE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SK&F 81297;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; HISTOLOGY; MALE; MOTOR DYSFUNCTION; NEUROMODULATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; ANIMAL; BRAIN LEVEL; DISEASE MODEL; DRUG EFFECT; HEMISPHERIC DOMINANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT; TIME;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENERGIC AGENTS; ANIMALS; BENZAZEPINES; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DESIPRAMINE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; FUNCTIONAL LATERALITY; MALE; MOVEMENT DISORDERS; OXIDOPAMINE; PARKINSON DISEASE; PIPERAZINES; PSYCHOMOTOR PERFORMANCE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 56249141071     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.031     Document Type: Article

References (58)

1. Albert P.R., Zhou Q.Y., Van Tol H.H., Bunzow J.R., and Civelli O. Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. J. Biol. Chem. 265 (1990) 5825-5832
2. Anderson K.D., and Reiner A. Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization. J. Comp. Neurol. 295 (1990) 339-369
3. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., and Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58 (2005) 193-199
4. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 57 (2005) 17-26
5. 1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Brain Res. 1127 (2006) 177-184
6. 1A agonist in advanced Parkinson's disease. Mov. Disord. 20 (2005) 932-936
7. 1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol. Dis. 23 (2006) 77-86
8. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57 (2001) 1829-1834
9. Bishop C., and Walker P.D. Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience 121 (2003) 649-657
10. 1A receptor stimulation. Eur. J. Neurosci. 23 (2006) 2669-2676
11. Cai G., Wang H.Y., and Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 302 (2002) 1105-1112
12. Calabresi P., Giacornini P., Centonze D., and Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?. Ann. Neurol. 47 Suppl. 1 (2000) S60-S68
13. Carta M., Carlsson T., Kirik D., and Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 (2007) 1819-1833
14. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
15. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 30 (2007) 236-243
16. Chang J.W., Wachtel S.R., Young D., and Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88 (1999) 617-628
17. Chase T.N., and Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23 (2000) S86-S91
18. Cho Y.H., Kim D.S., Kim P.G., Hwang Y.S., Cho M.S., Moon S.Y., et al. Dopamine neurons derived from embryonic stem cells efficiently induce behavioral recovery in a Parkinsonian rat model. Biochem. Biophys. Res. Commun. 341 (2006) 6-12
19. Dekundy A., Lundblad M., Danysz W., and Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 179 (2007) 76-89
20. Delfino M., Kalisch R., Czisch M., Larramendy C., Ricatti J., Taravini I.R., et al. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 32 (2007) 1911-1921
21. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 1158 (2007) 135-143
22. 1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl.) 199 (2008) 99-108
23. 1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 87 (2007) 306-314
24. Fiorentini C., Gardoni F., Spano P., Di Luca M., and Missale C. Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-d-aspartate receptors. J. Biol. Chem. 278 (2003) 20196-20202
25. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M., et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39 (2001) 288-296
26. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22 (2002) 5042-5054
27. Guigoni C., Doudnikoff E., Li Q., Bloch B., and Bezard E. Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol. Dis. 26 (2007) 452-463
28. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., and Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist(R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther. 319 (2006) 1225-1234
29. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20 Suppl. 11 (2005) S11-S16
30. 1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54 (2002) 133-137
31. Kilpatrick I.C., Jones M.W., and Phillipson O.T. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46 (1986) 1865-1876
32. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
33. Kreipke C.W., and Walker P.D. NMDA receptor blockade attenuates locomotion elicited by intrastriatal dopamine D1-receptor stimulation. Synapse 53 (2004) 28-35
34. Lane E.L., Cheetham S.C., and Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?. Exp. Neurol. 197 (2005) 284-290
35. Lundblad M., Anderson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
36. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., and Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 194 (2005) 66-75
37. Maeda T., Kannari K., Shen H., Arai A., Tomiyama M., Matsunaga M., et al. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett. 343 (2003) 17-20
38. 1A) receptors in human brain postmortem. Brain Res. 658 (1994) 55-59
39. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 1112 (2006) 126-133
40. Mela F., Marti M., Dekundy A., Danysz W., Morari M., and Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 101 (2007) 483-497
41. Mignon L.J., and Wolf W.A. 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. NeuroReport 16 (2005) 699-703
42. Mignon L., and Wolf W.A. Postsynaptic 5-HT(1A) receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for Parkinson's disease. Psychopharmacology (Berl.) 192 (2007) 49-59
43. Monville C., Torres E.M., and Dunnett S.B. Validation of the l-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 68 (2005) 16-23
44. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15 (1995) 3863-3875
45. Pasqualetti M., Nardi I., Ladinsky H., Marazziti D., and Cassano G.B. Comparative anatomical distribution of serotonin 1A, 1Da and 2A receptor mRNAs in human brain postmortem. Mol. Brain Res. 39 (1996) 223-233
46. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease. Neurology 67 (2006) 1612-1617
47. Paxinos G., and Watson W. The Rat Brain in Stereotaxic Coordinates. fourth ed. (1998), Academic Press, San Diego
48. Pollack A.E., and Yates T.M. Prior dopamine D1 receptor stimulation is required to prime D2-mediated striatal fos expression in 6-hydroxydopamine-lesioned rats. Neuroscience 94 (1999) 505-514
49. Queiroz C.M.T., Alcantara F.B., Yague A.M.L., Bibancos T., and Frussa-Filho R. Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice. Braz. J. Med. Biol. Res. 35 (2002) 237-242
50. Rascol O., Nutt J.G., Blin O., Goetz C.G., Trugman J.M., Soubrouillard C., et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch. Neurol. 58 (2001) 249-254
51. 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J. Nucl. Med. 47 (2006) 1697-1706
52. Santiago M., Matarredona E.R., Machado M., and Cano J. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J. Neurosci. Res. 52 (1998) 591-598
53. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
54. Tanaka Y., Kannari T., Maeda M., Tomiyama T., Suda M., and Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10 (1999) 631-634
55. Taylor J.L., Bishop C., and Walker P.D. Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav. 81 (2005) 887-893
56. Taylor J.L., Bishop C., Ullrich T., Rice K.C., and Walker P.D. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 50 (2006) 761-768
57. 1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease. Neurosci. Res. 52 (2005) 185-194
58. Westin J.E., Vercammen L., Strome E.M., Konradi C., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62 (2007) 800-810